CervoMed (CRVO) awards 8,150 stock options to new board director

Rhea-AI Filing Summary

CervoMed Inc. director Marwan Sabbagh reported receiving a grant of stock options as part of his board compensation. On June 8, 2026, he was awarded options to purchase 8,150 shares of CervoMed common stock at an exercise price of $2.91 per share. These options were granted under the company’s 2025 Equity Incentive Plan in line with its non-employee director compensation policy. The options vest in substantially equal monthly installments over one year, with 1/12 of the underlying shares vesting on the last day of each month beginning June 30, 2026, contingent on his continued board service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Sabbagh Marwan

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	8,150	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 8,150 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option shares granted: 8,150 shares Exercise price: $2.91 per share Expiration date: June 8, 2036 +1 more

4 metrics

Option shares granted 8,150 shares Stock option grant on June 8, 2026

Exercise price $2.91 per share Stock option exercise price

Expiration date June 8, 2036 Option term end date

Post-grant derivative holdings 8,150 options Total derivative securities following this transaction

Key Terms

2025 Equity Incentive Plan, non-employee director compensation policy, vest on a monthly basis, Stock Option (Right to Buy)

4 terms

2025 Equity Incentive Plan financial

"the Issuer's common stock under the Issuer's 2025 Equity Incentive Plan in accordance"

non-employee director compensation policy financial

"in accordance with the terms of the Issuer's non-employee director compensation policy"

vest on a monthly basis financial

"The shares of common stock underlying the award will vest on a monthly basis over a one-year period"

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sabbagh Marwan

(Last) (First) (Middle)

20 PARK PLAZA, SUITE 424

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CervoMed Inc. [ CRVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.91	06/08/2026		A		8,150		(1)	06/08/2036	Common Stock	8,150	$0	8,150	D

Explanation of Responses:

1. On June 8, 2026, in connection with the Reporting Person's election to the Issuer's board of directors at its 2026 Annual Meeting of Stockholders, the Reporting Person was granted an option to purchase 8,150 shares of the Issuer's common stock under the Issuer's 2025 Equity Incentive Plan in accordance with the terms of the Issuer's non-employee director compensation policy. The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2026, subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ William R. Elder, attorney-in-fact for the Reporting Person	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CervoMed (CRVO) report for director Marwan Sabbagh?

CervoMed reported that director Marwan Sabbagh received a grant of stock options. On June 8, 2026, he was awarded options to purchase 8,150 shares of common stock as part of his non-employee director compensation under the 2025 Equity Incentive Plan.

How many CervoMed (CRVO) shares are covered by Marwan Sabbagh’s new stock options?

The new option grant covers 8,150 shares of CervoMed common stock. These options were awarded upon his election to the board at the 2026 Annual Meeting and represent a routine equity component of non-employee director compensation.

What is the exercise price of Marwan Sabbagh’s CervoMed (CRVO) stock options?

The options have an exercise price of $2.91 per share. This means Sabbagh can purchase CervoMed common stock at $2.91 for each option share once the relevant portion of the award has vested, subject to the plan terms.

How do Marwan Sabbagh’s CervoMed (CRVO) stock options vest over time?

The 8,150-share option award vests monthly over one year. Vesting occurs in substantially equal 1/12th increments on the last day of each month, starting June 30, 2026, and is conditioned on his continued service on the board.

Under which plan were the CervoMed (CRVO) stock options granted to Marwan Sabbagh?

The options were granted under CervoMed’s 2025 Equity Incentive Plan. The grant follows the company’s non-employee director compensation policy, providing equity-based awards to outside directors in connection with their board service.

When do Marwan Sabbagh’s CervoMed (CRVO) stock options expire?

The option award is scheduled to expire on June 8, 2036. Until that expiration date, and subject to vesting and plan terms, Sabbagh may choose to exercise vested portions at the fixed $2.91 exercise price per share.